Gufic Group

Mumbai, India Founded: 1970 • Age: 56 yrs Listed
Lyophilized injections and pharmaceutical products are manufactured across therapeutic segments.
Request Access
Report Incorrect Data
Page last updated

About Gufic Group

Gufic Group is a publicly listed company based in Mumbai (India) founded in 1970. Lyophilized injections and pharmaceutical products are manufactured across therapeutic segments. The company has 1,990 employees. Its chief executive, as recorded, is Jayesh Choksi. Its Indian entity Gufic Biosciences Limited reported revenue of ₹947 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Injectables.

Company details

Founded in 1970 in Mumbai, India, pharmaceutical and herbal products including lyophilized injections are produced by the company. Operations center on a fully automated lyophilization plant that supports manufacturing in multiple therapeutic areas. Supplies are directed to major hospital chains and medical facilities. Research and development is conducted to develop new formulations and refine existing ones. Contract manufacturing of bulk drugs and active pharmaceutical ingredients is also handled.

  • Headquarters Mumbai, India
  • Employees 1,990
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website gufic.com
  • Social LinkedIn Facebook
  • Legal Name Gufic Biosciences Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹4,249 Cr

    GUFICBIO · NSE

  • Share Price
    ₹418.80

    -1.17% today

  • Revenue
    ₹944 Cr

    FY 2025-26 · +15.2% YoY

  • EBITDA
    ₹151 Cr

    Margin 16.0%

  • Net Profit
    ₹64.22 Cr

    FY 2025-26 · -7.6% YoY

  • P/E (TTM)
    57.4x

    P/B 6.3x

  • ROE
    10.1%

    ROCE 12.0%

  • Debt / Equity
    0.59

    Interest cover 30.4x

  • Employee Count
    1,990

Board of directors of Gufic Biosciences Limited (Gufic Group)

Gufic Biosciences Limited is the primary company behind Gufic Group. The board of Gufic Biosciences Limited currently have 6 directors; the longest-serving is Jayesh Pannalal Choksi, appointed in 1999. 17 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Jayesh Pannalal Choksi
DIN 00001729
Managing Director31 Aug 199927 yrs 1 moGufic Biosciences Limited
Pranav Jayesh Choksi
DIN 00001731
Whole-time director25 Jun 200422 yrs 4 moGufic Biosciences Limited
Pankaj Jayakumar Gandhi
DIN 00001858
Whole-time director01 Aug 201313 yrs 2 moGufic Biosciences Limited
Anu Sanjiv Aurora
DIN 05120192
Director23 Dec 20196 yrs 10 moGufic Biosciences Limited
Kamal Kishore Seth
DIN 00194986
Director27 Jun 20242 yrs 4 moGufic Biosciences Limited
Akshya Kumar Mahapatra
DIN 08362446
Director14 Nov 20241 yr 11 moGufic Biosciences Limited

People of Gufic Group

1 people are tracked at Gufic Group (1 in leadership); the tracked headcount is 1,990.

NameRoleGroup
Jayesh Choksi
Chairman & CEOLeadership
Premium access

Complete people profiles for Gufic Group

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Gufic Group

Gufic Group is a publicly listed company on the NSE with ticker symbol GUFICBIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 Oct 2004
  • Listed onNSE: GUFICBIO
  • Listed entityGufic Biosciences Limited
  • Exchange sectorHealth technology
  • ISININE742B01025
  • Share price₹417.10 (+1.12% on the day) · 2026-10-14
  • Market capitalisation₹4,161 Cr
  • Price to earnings56.9
  • EPS (diluted, trailing year)₹7.32
  • Dividend yield0.02%
  • Volume (last session)52,737

Financials of Gufic Group

Exchange-reported figures of Gufic Biosciences Limited, the listed company behind Gufic Group (NSE: GUFICBIO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹944 Cr
+15.1% YoY
EBITDA
₹151 Cr
+11.2% YoY
Profit After Tax
₹64.22 Cr
-7.6% YoY
Net Worth
₹665 Cr
+10.6% YoY
Total Assets
₹1,093 Cr
+13.9% YoY
Total Debt
₹405 Cr
+20.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24
Income statement
Revenue944820807
Revenue growth+15.2%+1.6%-
EBITDA151136147
EBITDA margin+16.0%+16.6%+18.3%
Profit before tax86.5594.13116
Net profit64.2269.4987.81
Net profit margin+6.8%+8.5%+10.9%
EPS (₹)6.406.958.59
Balance sheet
Total assets1,093960886
Net worth665601533
Total debt405336333
Cash & bank76.2229.0213.48
Net working capital570423396
Cash flow
Cash from operations45.14123(7.46)
Cash from investing(30.96)(70.78)(102)
Cash from financing32.29(37.20)82.38
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue261252231237224205208204
Revenue growth (YoY)+16.6%+22.8%+11.4%+16.1%+10.3%---
Other income0.46(1.17)0.792.120.930.391.860.11
EBITDA46.6147.2132.9837.8433.3026.3733.9238.62
EBITDA margin+17.9%+18.7%+14.3%+16.0%+14.9%+12.9%+16.3%+18.9%
Depreciation7.717.657.697.777.727.844.624.30
Interest9.329.448.369.589.238.404.915.18
Profit before tax30.0428.9517.7222.6117.2810.5226.2529.25
Tax7.737.055.305.784.202.806.967.49
Net profit22.3121.9012.4216.8313.087.7219.2921.76
EPS (₹)2.222.181.241.681.300.771.932.17
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue940820807691779488379
Revenue growth+14.7%+1.6%+16.8%-11.4%+59.8%+28.7%-
EBITDA15013614713514883.9252.12
EBITDA margin+16.0%+16.6%+18.3%+19.5%+19.0%+17.2%+13.8%
Profit before tax85.4994.4211610712757.7130.14
Net profit63.1669.7887.8179.6895.7944.2122.69
Net profit margin+6.7%+8.5%+10.9%+11.5%+12.3%+9.1%+6.0%
EPS (₹)6.306.978.598.229.894.562.34
Balance sheet
Total assets1,092960886700351250268
Net worth664601533348269173129
Total debt40533633333464.3961.54126
Cash & bank74.3628.2113.4746.6926.5713.1816.37
Net working capital568422396303150120134
Cash flow
Cash from operations44.19123(7.46)(26.59)10687.2547.10
Cash from investing(30.96)(71.79)(102)(191)(94.59)(6.69)(42.53)
Cash from financing32.19(37.20)82.38234(6.24)(78.62)(4.21)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue261252231230227205208204
Revenue growth (YoY)+14.9%+22.9%+11.2%+12.9%+11.9%---
Other income0.46(1.20)0.792.090.890.381.860.11
Total expenses214206195195195178174166
EBITDA46.7345.9136.3035.8032.3326.6433.9438.62
EBITDA margin+17.9%+18.2%+15.7%+15.5%+14.2%+13.0%+16.3%+18.9%
Depreciation7.717.657.697.777.727.844.624.30
Interest9.329.448.369.589.238.404.915.18
Profit before tax30.1627.6221.0420.5416.2710.7826.2729.25
Tax7.707.055.495.594.202.806.967.49

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue261252231237224205208204
Revenue growth (YoY)+16.6%+22.8%+11.4%+16.1%+10.3%---
Other income0.46(1.17)0.792.120.930.391.860.11
EBITDA46.6147.2132.9837.8433.3026.3733.9238.62
EBITDA margin+17.9%+18.7%+14.3%+16.0%+14.9%+12.9%+16.3%+18.9%
Depreciation7.717.657.697.777.727.844.624.30
Interest9.329.448.369.589.238.404.915.18
Profit before tax30.0428.9517.7222.6117.2810.5226.2529.25
Tax7.737.055.305.784.202.806.967.49
Net profit22.3121.9012.4216.8313.087.7219.2921.76
EPS (₹)2.222.181.241.681.300.771.932.17
ParticularsFY 2025-26FY 2024-25FY 2023-24
Revenue944820807
Revenue growth+15.2%+1.6%-
Other income2.663.632.18
Total expenses793684659
Employee cost152127110
EBITDA151136147
EBITDA margin+16.0%+16.6%+18.3%
Depreciation30.8321.0617.02
Interest36.6124.5216.79
Profit before tax86.5594.13116
Tax22.3324.4929.54
Net profit64.2269.4987.81
Net profit margin+6.8%+8.5%+10.9%
EPS (₹)6.406.958.59
ParticularsFY 2025-26FY 2024-25FY 2023-24
Equity & liabilities
Share capital10.0310.0310.03
Reserves & surplus655591523
Shareholders' funds (net worth)665601533
Minority interest0.040.000.00
Secured loans385310317
Unsecured loans19.5925.8215.88
Total debt405336333
Total liabilities1,093960886
Assets
Gross block630614246
Net block491506159
Capital work in progress22.1421.82307
Investments1.781.781.78
Inventories324217200
Sundry debtors297315330
Cash & bank balances76.2229.0213.48
Loans & advances10464.0256.58
Total current assets802625600
Total current liabilities233201205
Net working capital570423396
Total assets1,093960886
ParticularsFY 2025-26FY 2024-25FY 2023-24
Opening cash15.721.1428.60
Net cash from operating activities45.14123(7.46)
Net cash from investing activities(30.96)(70.78)(102)
Net cash from financing activities32.29(37.20)82.38
Net change in cash46.4614.59(27.47)
Closing cash76.2229.0213.48
ParticularsFY 2025-26FY 2024-25FY 2023-24
Growth
Sales growth+15.2%+1.6%-
EBITDA growth+11.2%-7.6%-
PBT growth-8.1%-18.6%+9997.0%
Net income growth-7.6%-20.9%-
Profitability & leverage
Net income margin+6.8%+8.5%+10.7%
Return on capital employed+12.0%+12.9%+15.0%
Return on net worth+10.1%+12.3%+16.2%
Debt / equity0.590.590.63
Long-term debt / equity0.210.280.31
Interest cover30.3821.3212.89
Efficiency & per share
Fixed asset turnover1.521.913.28
Inventory turnover3.493.934.02
Debtors turnover3.082.542.44
EPS (₹)6.406.958.59
Dividend per share (₹)0.100.100.10
Book value per share (₹)66.3159.9353.11
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue261252231230227205208204
Revenue growth (YoY)+14.9%+22.9%+11.2%+12.9%+11.9%---
Other income0.46(1.20)0.792.090.890.381.860.11
Total expenses214206195195195178174166
EBITDA46.7345.9136.3035.8032.3326.6433.9438.62
EBITDA margin+17.9%+18.2%+15.7%+15.5%+14.2%+13.0%+16.3%+18.9%
Depreciation7.717.657.697.777.727.844.624.30
Interest9.329.448.369.589.238.404.915.18
Profit before tax30.1627.6221.0420.5416.2710.7826.2729.25
Tax7.707.055.495.594.202.806.967.49
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue940820807691779488379
Revenue growth+14.7%+1.6%+16.8%-11.4%+59.8%+28.7%-
Other income2.583.622.182.573.103.735.79
Total expenses790683659556631404327
Employee cost15212711086.7385.6166.2258.59
EBITDA15013614713514883.9252.12
EBITDA margin+16.0%+16.6%+18.3%+19.5%+19.0%+17.2%+13.8%
Depreciation30.8321.0617.0222.2818.9316.3113.86
Interest36.6124.5216.798.225.3713.6313.91
Profit before tax85.4994.4211610712757.7130.14
Tax22.3324.4929.5427.0231.0013.487.44
Net profit63.1669.7887.8179.6895.7944.2122.69
Net profit margin+6.7%+8.5%+10.9%+11.5%+12.3%+9.1%+6.0%
EPS (₹)6.306.978.598.229.894.562.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.0310.0310.039.699.699.699.69
Reserves & surplus654591523338259164120
Shareholders' funds (net worth)664601533348269173129
Secured loans38531031731161.2455.35117
Unsecured loans19.5925.8215.8822.793.156.199.66
Total debt40533633333464.3961.54126
Total liabilities1,092960886700351250268
Assets
Gross block630614246229180149115
Net block49150615916011599.9782.58
Capital work in progress22.1421.8230717040.8713.4030.61
Investments2.872.811.790.780.010.010.01
Inventories32421720018311694.40122
Sundry debtors297315330205152124107
Cash & bank balances74.3628.2113.4746.6926.5713.1816.37
Loans & advances10464.0956.5828.5027.0628.5027.50
Total current assets800624600464321261273
Total current liabilities233201205161170140139
Net working capital568422396303150120134
Total assets1,092960886700351250268
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash14.911.1328.6011.616.204.263.90
Net cash from operating activities44.19123(7.46)(26.59)10687.2547.10
Net cash from investing activities(30.96)(71.79)(102)(191)(94.59)(6.69)(42.53)
Net cash from financing activities32.19(37.20)82.38234(6.24)(78.62)(4.21)
Net change in cash45.4213.78(27.48)16.995.411.940.36
Closing cash74.3628.2113.4746.6926.5713.1816.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.7%+1.6%+16.8%-11.4%+59.8%+28.7%-
EBITDA growth+10.2%-7.4%+9.4%-9.0%+76.4%+61.0%-
PBT growth-9.5%-18.4%+8.4%-15.9%+119.8%+91.5%-14.7%
Net income growth-9.5%-20.5%+10.2%-16.8%+116.7%+94.8%-
Revenue CAGR (3Y)+10.8%+1.7%+18.3%+22.2%+30.5%+16.9%+15.6%
EBITDA CAGR (3Y)+3.7%-2.7%+20.6%+37.2%+47.7%+29.4%+31.4%
Profitability & leverage
Net income margin+6.7%+8.5%+10.7%+11.5%+12.3%+9.1%+6.0%
Return on capital employed+11.9%+12.9%+16.7%+21.9%+44.0%+27.5%+19.7%
Return on net worth+10.0%+12.3%+19.6%+25.8%+43.3%+29.2%+22.2%
Debt / equity0.590.590.760.650.280.621.10
Long-term debt / equity0.210.280.420.410.200.210.18
Interest cover30.6321.2612.897.324.1620.1636.36
Efficiency & per share
Fixed asset turnover1.511.913.403.384.753.704.98
Inventory turnover3.473.934.204.627.424.503.50
Debtors turnover3.072.543.013.875.654.213.61
EPS (₹)6.306.978.598.229.894.562.34
Dividend per share (₹)0.100.100.100.100.100.100.05
Book value per share (₹)66.2359.9653.1135.8827.7617.8913.34

Web traffic of Gufic Group

The website of Gufic Group (gufic.com) receives about 8.5K visits a month and ranks #1,736,684 among all websites worldwide, #2,358 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    8.5K

    ▼ 31.1% vs previous month

  • Unique visitors
    6K

    per month

  • Global rank
    #1,736,684

    among all websites

  • Category rank
    #2,358

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Gufic Group. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Coherent Market Insights
coherentmarketinsights.com
100%
122.4K#372,291View details

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Gufic Group (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Gufic Group

Gufic Biosciences: Gets Three Observations From USFDA At Pithampur Production Site
Exchange Update • 6 days ago
GUFICBIO: Strong revenue and margin growth supported by capacity ramp-up and product innovation
Quartr • 2 months ago
GUFICBIO: Q1 FY27 saw double-digit revenue growth, margin expansion, and global scale-up from new capacity
Quartr • 2 months ago
Gufic BioSciences consolidated net profit rises 70.70% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 2 months ago
Gufic Biosciences June-Quarter Consol Total Profit 223.1 Million Rupees
Reuters • 2 months ago
GUFICBIO: Q1 FY27 saw strong profit growth and a major international expansion into the Philippines
Quartr • 2 months ago
GUFICBIO: Record Q4 results, margin expansion, and strong outlook with stable debt and no major CapEx
Quartr • 5 months ago
GUFICBIO: Q4 FY26 saw strong revenue and profit growth, led by Indore facility ramp-up and segment expansion
Quartr • 5 months ago
GUFICBIO: Record Q4 performance and strategic shifts set the stage for margin and revenue growth in FY 2027
Quartr • 5 months ago
GUFICBIO: Double-digit revenue growth and expanded capacity, with focus on scaling output and global markets
Quartr • 5 months ago
Premium access

Complete news archive for Gufic Group

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gufic Group

Gufic Group was founded in 1970.

Gufic Group is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Jayesh Choksi is the CEO of Gufic Group, as recorded in our data.

Gufic Group has 1,990 employees.

The primary company behind Gufic Group, Gufic Biosciences Limited, reported revenue of ₹947 Cr for FY 2026, up 15% year on year.

Founded in 1970 in Mumbai, India, pharmaceutical and herbal products including lyophilized injections are produced by the company. Operations center on a fully automated lyophilization plant that supports manufacturing in multiple therapeutic areas. Supplies are directed to major hospital chains and medical facilities. Research and development is conducted to develop new formulations and refine existing ones. Contract manufacturing of bulk drugs and active pharmaceutical ingredients is also handled.

Yes, Gufic Group is publicly traded on NSE under the ticker symbol GUFICBIO.

Gufic Group operates through Gufic Biosciences Limited.

The legal entities of Gufic Group currently have 8 directors, including Pranav Jayesh Choksi, Anu Sanjiv Aurora, Pankaj Jayakumar Gandhi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available